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Abstract. Members of the FGF family of growth fac- 
tors localize to the nuclei in a variety of different cell 
types. To determine whether FGF receptors are also 
present within nuclei and if this localization is regulated 
by FGFs, nuclei were prepared from quiescent and 
FGF-2-treated Swiss 3T3 fibroblasts and examined for 
the presence of FGF receptors by immunoblotting with 
an antibody produced against the extracellular domain 
of FGF receptor-1 (FGFR-1). Little or no FGFR-1 is 
detected in nuclei prepared from quiescent cells. When 
cells are treated with FGF-2, however, there is a time- 
and dose-dependent increase in the association of 
FGFR-1 immunoreactivity with the nucleus. In con- 
trast, treatment with either EGF or 10% serum does 
not increase the association of FGFR-1 with the nu- 
cleus. When cell surface proteins are labeled with bi- 
otin, a biotinylated FGFR-1 is detected in the nuclear 
fraction prepared from FGF-2-treated, but not un- 
treated, cells indicating that the nuclear-associated 
FGFR-1 immunoreactivity derives from the cell sur- 
face. The presence of FGFR-I in the nuclei of FGF- 
2-treated cells was confirmed by immunostaining with 
a panel of different FGFR-1 antibodies, including one 
directed against the COOH-terminal domain of the 
protein. Fractionation of nuclei from FGF-2-treated 
cells indicates that nuclear FGFR-1 is localized to the 
nuclear matrix, suggesting that the receptor may play a 
role in regulating gene activity. 
T 
HE FGFs are a family of heparin-binding polypep- 
tides that play a role in a wide array of biological 
processes, including cell growth, differentiation, an- 
giogenesis, tissue repair, and transformation (for reviews 
see  Baird and  Bohlen, 1990;  Burgess and Maciag,  1989; 
Wagner, 1991; Fernig and Gallagher, 1994). The FGFs in- 
teract with two classes of FGF receptors: high affinity re- 
ceptors that  bind FGFs with  picomolar affinity and  are 
thought to mediate the cellular responses to FGF, and low 
affinity receptors that bind FGFs with nanomolar affinity 
and are characterized by the presence of heparan sulfate 
moieties. At the present time, the high affinity FGF recep- 
tor family contains four members (for reviews see Johnson 
and Williams,  1993;  Givol and Yayon, 1992; Partanen et 
al., 1993). In addition, alternative splicing can generate re- 
ceptor isoforms that vary in their extra- or intracellular do- 
mains. Each of these receptors is capable of binding and 
responding to more than one type of FGF. Similar to other 
growth factor receptors, the FGF receptors possess intrin- 
sic tyrosine kinase activity. Thus, FGF binding to the ex- 
tracellular domain of a receptor rapidly leads to receptor 
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autophosphorylation and substrate tyrosine phosphoryla- 
tion. However, long-term treatment of cells with FGFs is 
necessary for cells to show a mitogenic response (Zhan et 
al.,  1993; Presta et al.,  1991) suggesting that signals other 
than those provided by direct receptor activation are re- 
quired for cell proliferation. 
Some of the mitogenic signals may be provided by FGFs 
themselves.  Unlike  other  growth  factors,  internalized 
FGFs are surprisingly stable, persisting in treated cells for 
many hours (Walicke and Baird, 1991; Friesel and Maciag, 
1988;  Moenner et al.,  1989).  A  number of studies  have 
demonstrated  the  presence of FGF-1  (aFGF)  or FGF-2 
(bFGF)  in  the  nuclei  of cells  (Florkiewicz  et  al.,  1991; 
Tessler and Neufeld, 1990; Renko et al., 1990). In cells that 
produce FGF-2, the higher molecular mass isoforms (24, 
23, and 22 kD) are found exclusively in the nucleus (Flor- 
kiewicz et al., 1991; Renko et al., 1990). The addition of 18 
kD FGF-2 to target cell cultures results in uptake of a por- 
tion of the growth factor into the nucleus (Baldin et al., 
1990;  Walicke  and Baird,  1991).  In  some cell types, the 
translocation of FGF-2 to the nucleus is cell cycle depen- 
dent (Baldin et al., 1990). Similar results are obtained after 
treating cells with FGF-1 (Zhan et al., 1992). Furthermore, 
there is some evidence that this translocation of FGF-2 to 
the nucleus is required for the induction of cell prolifera- 
tion (Wiedlocha et al., 1994). 
Since the pathways whereby FGFs travel from the cell 
surface to the nucleus have not been described, the studies 
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ity FGF receptors could play a  role in this translocation. 
For these  experiments, we used mouse  Swiss 3T3  fibro- 
blasts, which express relatively high levels (Maher,  1993) 
of FGF receptors and respond to treatment with FGF-2 by 
an increase in DNA synthesis (Pasquale et al., 1988).  The 
nuclei  of these cells were isolated and examined for the 
presence  of  FGF  receptors.  Quiescent  fibroblasts  have 
very low levels of nuclear receptors. After stimulation with 
FGF-2, however, we found a dose and time dependent in- 
crease in nuclear FGF receptors. At least some of these re- 
ceptors appear to come from the cell surface. Within the 
nuclei, the receptors are found in the nuclear matrix, a re- 
gion of the nucleus implicated in tissue- and cell type-spe- 
cific gene expression (Dworetsky et al., 1990). 
Materials and Methods 
Cell Culture 
Swiss 3T3 fibroblasts (No.  CCL-92; American Type Culture Collection, 
Rockville, MD) were grown in DME containing 10% FCS and antibiotics. 
To prepare quiescent cells, Swiss 3T3 cells were grown to confluence and 
then incubated in 0.5% FCS for 48 h. 
Antibodies 
A  rabbit polyclonal antibody to the carboxyl terminus of FGF receptor-1 
(FGFR-1) was produced using a peptide containing the COOH-terminal 
17 amino acids of human FGFR-1 coupled to keyhole limpet hemocyanin. 
The antibody was affinity purified by passage over a column of the pep- 
tide coupled to Affigel 102. A  second rabbit polyclonal antibody to the 
COOH-terminal 15 amino acids of human FGFR-1  was obtained from 
Santa Cruz Biotechnology (Santa Cruz, CA) and was used for the immu- 
noprecipitation studies. A  mouse mAb against the baculovirus-expressed 
extracellular domain of FGFR-1  produced in insect cells (Kiefer et al., 
1991)  was generated using standard techniques and has been described 
elsewhere (Hanneken et al., 1995). 
Isolation of Nuclei 
Nuclei were isolated from Swiss 3T3 flbroblasts by several different tech- 
niques. In all cases, the integrity and quality of the nuclei were evaluated 
by light microscopy. In most cases, the purity of the nuclear fractions was 
also assessed by immunoblotting with an anti-EGF receptor antibody and 
assaying 5' nucleotidase activity (Sigma Diagnostics, St.  Louis, MO)  as 
markers for plasma membrane contamination and by assaying acid phos- 
phatase activity (Sigma Diagnostics) as a marker for lysosomal contami- 
nation. Neither EGF receptors (see Fig.  1) nor 5'  nucleotidase activity 
were detected in the nuclear fraction, and <5%  of the total acid phos- 
phatase activity was associated with the nuclear fraction. For most experi- 
ments, we used a rapid method that allows isolation of nuclei from small 
numbers of cells (Schreiber et al., 1989).  Briefly, cells in 35-mm culture 
dishes were rinsed twice with TBS and suspended in 200 Ixl cold homoge- 
nization buffer (t0 mM Hepes, pH 7.9,  10 mM KCI, 0.1 mM EDTA, 0.1 
mM EGTA, 1 mM DTT, 0.5 mM PMSF) by gentle scraping with a rubber 
policeman. The cells were allowed to swell on ice for 15 min, at which 
time, 12.5 ixl of a 10% solution of NP-40 was added and the tube was vor- 
texed vigorously for 10 s. Nuclei were pelleted by centrifugation for 30 s in 
a microfuge, washed twice with homogenization buffer containing NP-40, 
and  resuspended  in  200  p,1  homogenization  buffer  containing  NP-40. 
Equal volumes of the nuclear and nonnuclear fractions were solubilized in 
2.5X Laemmli sample buffer and were analyzed by SDS-PAGE and im- 
munoblotting with the monoclonal anti-FGFR antibody (see below). For 
nuclear  fractionation,  membrane-depleted  nuclei  were  isolated  as  de- 
scribed  (Fey  et  al.,  1986).  Briefly,  cells in  60-mm culture  dishes were 
washed twice with PBS, suspended in CSK 100 buffer (100 mM NaC1, 300 
mM sucrose, 3 mM MgCI2, 1% Triton X-100, 0.5 mM CaCI2, 10 mM Pipes, 
1.2 mM PMSF, pH 6.8), incubated 7 min on ice, and nuclei were collected 
by centrifugation at 650 g for 5 min at 4°C. Nuclear matrices were isolated 
from membrane-depleted nuclei as described  (Dworetsky  et  al.,  1990). 
The nuclei were treated first with a double detergent buffer (0.5% deoxy- 
cholate/1% Tween 40 in 10 mM Tris-HCl, 10 mM NaCI, 3 mM MgCI2, pH 
7.4)  to  remove  cytoskeletal  elements and  polyribosomes, then  resus- 
pended in CSK 50 buffer (50 mM NaC1,  300 mM sucrose, 3 mM MgCI2, 
1% Triton X-100, 0.5 mM CaC12, 10 mM Pipes, 1.2 mM PMSF, pH 6.8) 
containing 100 p~g/ml DNase I and 50 Ixg/ml RNase A, incubated for 20 
min at 37°C, and then ammonium sulfate was added to a final concentra- 
tion of 0.25  M. After 15 min on ice, nuclear matrices were collected by 
centrifugation. In some experiments, the peripheral nuclear matrix was 
prepared by extracting intact matrices with 0.25 M ammonium sulfate and 
40 mM DTT in CSK 50 buffer for 20 min at 37°C and collecting by centrif- 
ugation (Payrastre et al., 1992).  Equal amounts of protein from all the 
fractions were solubilized in 2.5 x  Laemmli sample buffer and analyzed by 
SDS-PAGE and immunoblotting with the monoclonal anti-FGFR-1 anti- 
body. For immunoblotting, the transfers were stained with amido black to 
confirm the presence of equal amounts of protein in each lane and then 
blocked with 5% nonfat milk in TBS overnight before incubation with an- 
tibodies. The transfers were incubated overnight with the antibody (3 Isg/ 
ml), washed, and then incubated with rabbit anti-mouse IgG (1 ixg/ml) for 
2 h before the addition of 125I-protein A (0.2 ixCi/ml) for 2 h. The transfers 
were autoradiographed overnight at -70°C. 
Biotinylation of Cell-surface Proteins 
Quiescent Swiss 3T3 cells in 60-mm dishes were labeled for 30 min at 4°C 
with 0.5 mg/ml NHS-sulfo biotin (Vector Laboratories, Burlingame, CA) 
(Cole et al., 1987; Hurley et al., 1985),  rinsed with ice-cold PBS, and then 
incubated for 60 min in DME with 0.5% FCS at either 4°C or 37°C in the 
absence or presence of FGF-2. The cells were rinsed in ice-cold TBS, and 
the nuclei were prepared as described above. The nuclei were solubilized 
by sonication in RIPA buffer (150 mM NaCI, 20 mM Na2HPO4, pH 7.4, 
1% deoxycholate, 1% Triton X-100, 0.1% SDS, 1 mM Na3VO4),  and in- 
soluble material was removed by centrifugation. Biotin-tagged proteins 
were  precipitated  from the nuclear and nonnuclear fractions overnight 
with avidin-agarose (Vector Laboratories) and then eluted from the beads 
by boiling for 5 min in 2.5x Laemmli sample buffer. Samples were ana- 
lyzed  by  SDS-PAGE  and  immunoblotting with  the  monoclonal  anti- 
FGFR antibody, as described above. 
Immunofluorescence Microscopy 
Cells were treated as described in Results, rinsed in PBS, fixed for 5 rain 
with 3%  formaldehyde in PBS, and permeabilized for 5 min with 0.5% 
Triton X-100. Permeabilized cells were treated with either a rabbit anti- 
FGFR-1 antibody (10 ~g/ml) in PBS/3%  BSA or the monoclonal anti- 
FGFR-1 antibody (50 p~g/ml) in PBS/3% BSA for 30 min, rinsed in PBS, 
labeled with either a mixture of rhodamine-conjugated, affinity-purified 
F(ab)2 fragment of goat anti-rabbit IgG (8 p,g/ml) and nitrobenzoxadia- 
zole (NBD)-phaUacidin (20 U/ml) in PBS/3% BSA (for the polyclonal an- 
tibody), or fluorescein-conjugated donkey anti-mouse IgG (for the mAb) 
for 10 min and mounted in 90% glycerol. In some cases, the polyclonal 
anti-FGFR-1  antibody was preincubated with the peptide  antigen (100 
~g/ml) before labeling of the cells. Labeled cells were examined with ei- 
ther a microscope (Carl Zeiss, Inc., Thornwood, NY) using a ×63, numer- 
ical aperture 1.4 planapochromat oil objective for standard immunofluo- 
rescence microscopy, or with a laser scanning confocal microscope (model 
MRC600; Bio Rad Laboratories, Hercules, CA) equipped with an argon/ 
krypton mixed gas laser. Optical sections were taken in 400-nm steps in 
the z axis. Dual images were collected at 480 nm (NBD-phallacidin) and 
560 nm (rhodamine) and photographed. 
FGF Receptor Immunoprecipitation and In Vitro 
Kinase Assays 
Nuclear proteins were solubilized by sonication of isolated nuclei in Tri- 
ton X-100 buffer (1% Triton X-100 in 50 mM Hepes, pH 7.5, 50 mM NaCl, 
5 mM EDTA, 1 mM Na3VO4). FGFR-1 was immunoprecipitated at 4°C 
overnight with the commercial anti-FGFR-1 antibody (0.5 p.g/500 I~l nu- 
clear extract) or an equal amount of normal rabbit IgG, and the immuno- 
precipitates were collected on protein A-Sepharose and then washed 3× 
with 0.1% Triton X-100 in 20 mM Hepes, pH 7.5, 150 mM NaCl. In some 
experiments, 5 tLg of the cognate peptide was included during the immu- 
noprecipitation step. The immune complexes were resuspended in 50 I~l in 
vitro phosphorylation buffer (150 mM NaC1, 20 mM Hepes, pH 7.5, 0.1% 
Triton X-100) containing 10 mM MnC12, 50 mM MgC12, 50 nM ATP, and 1 
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ture with continuous rotation and then terminated by the addition of an 
equal volume of 5×  SDS sample buffer. The samples were separated on 
SDS-7.5% polyacrylamide gels, and the gels were fixed overnight in 25% 
methanol, 10% acetic acid, dried, and autoradiographed for 12-18 h. 
Protein Tyrosine Kinase Assays 
Protein tyrosine kinase activity in nuclei and nuclear matrices was assayed 
as described (Maher, 1991) using poly Glu/Tyr (4:1) as a substrate. The re- 
actions were  analyzed by SDS-PAGE and autoradiography, after which 
the substrate bands were cut from the gel and the incorporation of 32p was 
quantified by Cerenkov counting. 
Results 
To determine if the treatment of cells with FGF-2 causes a 
redistribution  of high  affinity FGF receptors  to  the  nu- 
cleus, quiescent Swiss 3T3 fibroblasts were treated for 60 
min with FGF-2, and the cells  separated into nuclear and 
nonnuclear fractions using a protocol for the rapid prepa- 
ration  of  membrane-depleted  nuclei  (Schreiber  et  al., 
1989).  Inspection of isolated  nuclei  by light  microscopy 
showed they were intact and free of membrane contami- 
nation (not shown). In addition, no 5' nucleotidase activity 
or EGF receptors were associated with the nuclei (Fig.  1 
B), although similar numbers of EGF and FGF receptors 
are  found on Swiss  3T3  cells  (unpublished  data).  Equal 
volumes from each fraction were  analyzed for the  pres- 
ence of FGF receptors by immunoblotting with an mAb 
prepared against a baculovirus-expressed extracellular do- 
main of FGFR-1 that is produced in insect cells. As shown 
in Fig. 1 A, little or no receptor is detectable in nuclei iso- 
lated from quiescent cells, whereas receptor is readily visu- 
alized  in  the  nuclear  fraction  prepared  from  FGF-2- 
treated  cells.  In  both  cases,  the  majority of receptor  is 
Figure 1.  Presence  of FGF receptors  in nuclei of FGF-treated 
Swiss 3T3 fibroblasts. (A) Quiescent cells were untreated  (ct) or 
treated  with 15 ng/ml FGF-2, 15 ng/ml EGF, or 10% FCS for 60 
min at 37°C. The cells were separated into nuclear (N) and non- 
nuclear  (C) fractions as described  (Schreiber et al., 1989), and 
equal volumes from each fraction were analyzed for the presence 
of FGF receptors  by SDS-PAGE and  immunoblotting  with  a 
mAb against the extracellular domain of FGFR-1. (B) Quiescent 
cells were untreated  (ct) or treated  with 15 ng/ml FGF-2 for 60 
min at 37°C. The cells were separated  into nuclear (N) and non- 
nuclear (C) fractions as described above, and equal volumes from 
each fraction were analyzed for the presence of EGF receptors by 
SDS-PAGE and immunoblotting with a mAb against the extra- 
cellular domain of EGFR. Arrowhead indicates position of EGFR. 
Similar results were obtained  in three independent  experiments 
of identical design. Molecular mass markers (in kilodaltons) are 
on the right. 
found in the soluble fraction that contains both solubilized 
plasma  membranes  and  cytoplasm.  The  two  bands  de- 
tected with the antibody correspond to the two and three 
Ig loop forms  of FGFR-1  (unpublished  data).  It is  not 
clear why the amounts of the two forms of FGFR-1 differ 
slightly between experiments, but it may result from the 
use of different batches of Swiss 3T3 cells. Since these cells 
fairly rapidly lose their strong mitogenic response to FGFs 
because  of  a  greatly  increased  basal  growth  rate,  new 
batches  of cells  must  be  thawed  quite  frequently.  The 
translocation of FGF receptor to the nucleus was specific: 
treatment with either EGF or 10% serum, two agents that 
also induce proliferation of the Swiss  3T3 cells,  does not 
increase the levels of FGF receptor in the nucleus. Treat- 
ment of cells with FGF-1 in the presence of heparin also 
causes  a  similar  increase  in  nuclear FGF receptors  (not 
shown). The presence of FGF receptors in the isolated nu- 
clei is unlikely to be an artifact of the technique used for 
nuclear isolation, since similar results were obtained using 
several different methods to prepare membrane-depleted 
nuclei (e.g.,  Fig. 6), and the biochemical results were con- 
firmed  by  immunofluorescence microscopy (see  Figs.  4 
and 5). 
The appearance of FGF receptors in the nucleus after 
treatment with FGF-2 was time and dose dependent (Fig. 
2).  Receptor is detected in the nucleus within  10 min of 
FGF-2 treatment, and maximal levels are reached within 1 h 
(Fig. 2 A). Extended treatment with FGF-2 (up to 10 h) 
does not result in a further increase in the level of nuclear 
FGFR-1  (not  shown).  Only a  slight  increase  in  nuclear 
FGF receptors is detected after a treatment with 1-5 ng/ml 
FGF-2, whereas a  strong nuclear signal is observed after 
stimulation with 15 or 50 ng/ml FGF-2 (Fig.  2 B). Under 
the  conditions  used  for  these  experiments,  15  ng/ml  of 
FGF-2 is the optimal mitogenic dose for Swiss 3T3 fibro- 
blasts (Pasquale et al., 1988). 
To determine if the nuclear FGF receptor immunoreac- 
tivity derives from the cell surface, FGF receptors on the 
surface of quiescent 3T3 cells were labeled with an imper- 
meable biotin analogue (Cole et  al.,  1987;  Hurley et al., 
1985)  before  treatment  with  FGF-2.  Biotin-labeled,  un- 
treated, and FGF-2-treated cells  were separated into nu- 
clear and nonnuclear fractions, and the biotin-tagged pro- 
teins  in  each  fraction were  collected  on  avidin-agarose. 
The fractions were analyzed for the presence of FGF re- 
ceptors by immunoblotting. As shown in Fig. 3, little or no 
biotin-tagged receptor is detected in the nuclei of quies- 
cent cells. However, a biotin-tagged receptor is clearly de- 
tectable in nuclei isolated from FGF-2-treated cells. These 
experiments  also demonstrate  that  a  significant percent- 
age (~30 %) of the cell-surface FGFR-1 migrates to the 
nucleus. No receptor is detectable in avidin-agarose pre- 
cipitates that were prepared from cells not labeled with bi- 
otin. In addition, little or no biotin-tagged receptor is de- 
tectable in the nuclei of cells treated with FGF-2 at a low 
temperature (4°C). 
Standard  and  confocal  immunofluorescence  micros- 
copy were  used  to provide further evidence that FGF-2 
stimulates  the  accumulation  of FGF receptors  in  target 
cell nuclei. Quiescent Swiss 3T3 cells show a diffuse label- 
ing for FGFR-1 (Fig. 4 A). The low level of plasma mem- 
brane staining is a result of the technique used to perme- 
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FGF receptors in the nuclei of Swiss 3T3 fibro- 
blasts.  Quiescent  cells  were  untreated  (ct)  or 
treated with 15 ng/ml FGF-2 for 10 min, 60 min, 2 
h, and 4 h  before fractionation and analysis  of 
equal volumes from each fraction for the pres- 
ence of FGF receptors. (B) Dose-dependent ac- 
cumulation  of FGF  receptor  in  the  nuclei  of 
Swiss 3T3 fibroblasts.  Quiescent cells  were un- 
treated (ct) or treated for 60 min with 5, 15, or 50 
ng/ml FGF-2 before fractionation and analysis of 
equal volumes from each fraction for the pres- 
ence of FGF receptors. Similar  results were ob- 
tained in three independent experiments  of identi- 
cal design. Molecular mass markers (in kilodaltons) 
are on the right. 
abilize  the cells.  After treatment  with FGF-2 for 10 min, 
some cells show an increase in perinuclear labeling (Fig. 4 
B). After 60 min, most cells show strong nuclear labeling 
for FGFR-1 (Fig. 4 C). Little or no labeling is seen in cells 
labeled  with  blocked  antibody  (Fig.  4  D), providing fur- 
ther evidence for the specificity of the nuclear labeling. To 
provide  additional  confirmation  for  the  localization  of 
FGFR-1 within the nuclei of FGF-2-treated cells, the cells 
were optically sectioned using a  confocal microscope. As 
shown in Fig. 5, the majority of the labeling for FGFR-1 is 
found within the nucleus. Some perinuclear staining is also 
observed. Qualitatively similar results were obtained with 
the monoclonal FGFR-1  antibody,  although the intensity 
of labeling was weaker (not shown). 
Since  theses  studies  clearly  establish  the  presence  of 
FGF receptors within the nuclei of fibroblasts after treat- 
ment with FGF-2, it was of interest to determine the sub- 
nuclear  localization of the  receptor.  Membrane-depleted 
nuclei were isolated from untreated and FGF-treated cells 
and  then  fractionated  further,  as  described  in  Materials 
and  Methods.  Using this  approach,  the  majority  of FGF 
receptor immunoreactivity is detected in the nuclear ma- 
trix  (Fig.  6).  Further  fractionation  of the  nuclear  matrix 
into  peripheral  matrix  and  internal  matrix  (Payrastre  et 
al.,  1992)  demonstrates  the  presence  of FGFR-1  immu- 
noreactivity exclusively in the peripheral matrix (Fig. 6), a 
fraction that represents  <5%  of the total cellular protein. 
The membrane-depleted nuclei (Fig. 6, lanes I  and 5) iso- 
lated by this technique (Fey et al., 1986) are not as clean as 
those prepared by hypotonic lysis (Schreiber et al.,  1989) 
and shown in Figs. 1-3. Thus, a low level of FGF receptor 
is detected in the unfractionated  nuclei isolated from un- 
treated cells. 
To determine if nuclear FGFR-1 retains tyrosine kinase 
activity, nuclei were solubilized  by sonication in a  deter- 
gent-containing buffer, FGFR-1  was immunoprecipitated 
with an antibody directed against the COOH terminus of 
FGFR-1, and the immunoprecipitate was assayed for auto- 
phosphorylation activity. As shown in Fig. 7, two high mo- 
lecular weight phosphorylated bands, similar in size to the 
two FGFR-1 bands detected by immunoblotting (Figs. 1- 
3), are seen in receptor immunoprecipitates prepared with 
nuclei isolated from FGF-2-treated cells. These bands are 
greatly reduced or absent in receptor immunoprecipitates 
prepared  with  nuclei  isolated  from  quiescent  Swiss  3T3 
cells.  The  additional  protein  bands  that  immunoprecipi- 
tate with FGFR-1 may represent nuclear substrates of the 
receptor.  Only  lower  molecular  weight  phosphorylated 
bands  are seen  in control immunoprecipitates  using nor- 
mal rabbit IgG, and few or no phosphorylated bands are 
seen  in  control  immunoprecipitates  formed  in  the  pres- 
ence of the cognate peptide. 
These  results  suggested  that  the  translocation  of FGF 
receptor to the nucleus might result in a  general increase 
in tyrosine kinase activity in the nuclear fractions. To test 
this  idea,  nuclei,  nuclear  matrix,  and  peripheral  nuclear 
matrix  isolated  from  untreated  and  FGF-2-treated  cells 
were  assayed for tyrosine kinase  activity using poly Glu/ 
Tyr (4:1) as an exogenous substrate. Tyrosine kinase activ- 
ity is increased in both the nuclei and nuclear matrix iso- 
Figure 3.  Translocation of FGF receptors from 
the cell surface to the nucleus.  Quiescent Swiss 
3T3 cells were unlabeled (lanes 1, 3, 5, and 7) 
or labeled (lanes 2, 4, 6, and 8) with NHS-sulfo 
biotin at 4°C, and then incubated for 60 min at 
either 37°C (A) or 4°C (B) in the absence (lanes 
1-4) or presence (lanes 5-8) of 50 ng/ml FGF-2. 
Cells were fractionated, and biotin-labeled pro- 
teins in both the nuclear (lanes 3, 4, 7, and 8) 
and nonnuclear (lanes 1, 2, 5, and 6) fractions 
were precipitated with avidin-agarose. The pre- 
cipitates  were  analyzed  for  the  presence  of 
FGF  receptors  by  SDS-PAGE and  immuno- 
blotting with the mAb against the extracellular  domain of FGFR-1. Similar results were obtained in three independent experiments  of 
identical design. Molecular mass markers (in kilodaltons) are on the right. 
The Journal of Cell Biology,  Volume 134, 1996  532 Figure 4.  Indirect immunofluorescence labeling  of Swiss 3T3 fibroblasts  for FGF receptors. Quiescent cells were untreated (A) or 
treated for 10 min (B) or 60 min (C and D) with 50 ng/ml FGF-2, and then labeled with the rabbit polyclonal FGFR-1 antibody in the ab- 
sence (A-C) or presence (D) of the cognate peptide. Similar results were obtained in three independent experiments of identical design. 
lated from FGF-treated cells, and is highest relative to un- 
treated  cells  in  the  peripheral  nuclear  matrix  fraction 
(Table I). The increase in tyrosine kinase activity is consis- 
tent with the presence of FGFR-1 in these fractions (Fig. 
6). The marginal increase in tyrosine kinase activity seen 
in whole nuclei isolated from FGF-2-treated cells proba- 
bly  reflects  the  presence  of multiple  tyrosine  kinases  in 
whole nuclei, as well as the presence of low levels of FGF 
receptor  in  nuclei  isolated  from  untreated  cells  by  this 
technique. 
Discussion 
The results presented here provide strong evidence for an 
FGF-2-dependent  translocation  of high  affinity FGF re- 
ceptors to the nuclei of fibroblasts. Their subnuclear asso- 
ciation with the nuclear matrix suggests that FGF recep- 
tors may play a direct role in regulating gene transcription. 
In addition, these findings may help explain a  number of 
paradoxes regarding the effects of FGF on cells (e.g., Zhan 
et al., 1993; Wiedlocha et al., 1994). 
Several  lines  of  evidence  indicate  that  the  FGF-2- 
dependent association of FGF receptors with nuclei is un- 
likely to be an artifact. First, several different methods for 
preparation of nuclei give similar results. In addition, frac- 
tionation of the nuclei indicates that the vast majority of 
nuclear  FGF  receptor  is  located  in  the  nuclear  matrix. 
Since preparation of this nuclear fraction removes >95% 
of the cellular proteins, any protein that is nonspecifically 
associated with the  nucleus  would  be unlikely to persist 
throughout  this fractionation. Furthermore, nuclear FGF 
receptors can be detected both by biochemical analysis of 
the nuclei by either immunoblotting or immunoprecipita- 
tion  and  in  vitro  phosphorylation,  and  by  immunocy- 
tochemistry with two distinct FGF receptor antibodies. Fi- 
nally, the presence of FGF receptors in the nuclei is ligand 
dependent, with little or no receptor detected in the nuclei 
of quiescent cells. 
The FGF-2-dependent  translocation  of FGF receptors 
observed in this study is distinct from the FGF-1--depen- 
dent association of FGF receptors with the perinuclear re- 
gion of NIH 3T3 cells (Prudovsky et al., 1994).  For exam- 
ple,  the  time course of FGF-2--dependent FGF receptor 
translocation to the nucleus is faster than that reported for 
FGF-1  stimulation  of receptor translocation  in  NIH 3T3 
cells (Prudovsky et al., 1994).  Maximal translocation is ob- 
served by 1 h  after the addition of FGF-2 with no further 
increase with longer treatment times, whereas at least a 9 h 
treatment with FGF-1 is required for maximal association 
of FGF receptors with the nuclei of NIH 3T3 cells. A  more 
significant difference between the two studies is the  ulti- 
mate location of translocated receptor. Using immunocy- 
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croscopy of FGF receptors in  FGF-2-treated 
Swiss 3T3 cells. Cells treated for 60 rain with 50 
ng/ml FGF-2 were labeled with the rabbit poly- 
clonal FGFR-1 antibody (B and D) and NBD- 
phallacidin (A and C), and were examined with 
a Bio Rad MRC600 laser scanning confocal mi- 
croscope.  Median nuclear optical  sections  are 
shown. 
tochemistry, enzymology, and biochemistry, I detect FGF 
receptors within  the  nucleus  associated with the  nuclear 
matrix. In response to FGF-1, receptors are translocated 
to a perinuclear region (Prudovsky et al., 1994).  Although 
this difference could be caused by different receptor anti- 
bodies,  I  obtain  the  same  immunocytochemical  results 
with two different antibodies. It is unlikely the difference 
is caused by differences in the FGF receptors on the two 
cell  types,  since  Swiss  3T3  fibroblasts  express  predomi- 
nantly FGFR-1  (unpublished  results), similar to the NIH 
3T3 cells. The nuclear FGFR-1 seen in the Swiss 3T3 cells 
also appears to be distinct from the nuclear FGFR-3 ob- 
served in breast epithelial cells (Johnston et al., 1995).  In 
the  latter  case, the  receptor in  the  nucleus  is  a  smaller, 
novel, intracellular form of FGFR-3 whereas, in the Swiss 
3T3 cells, nuclear FGFR-1 is caused by ligand-dependent 
translocation of the receptor from the cell surface to the 
nucleus. 
Although this is the first report of the FGF-2-dependent 
translocation  of FGF  receptors  into  the  nuclei  of cells, 
other  growth factor receptors have been reported  to be 
translocated to the nucleus in a ligand-dependent manner 
(Hopkins, 1994).  Insulin receptors (Podlecki et al.,  1987; 
Marti  et al.,  1991),  EGF receptors (Jiang and  Schindler, 
1990; Rakowicz-Szulczynska et al., 1989; Holt et al., 1994), 
HER2/neu (Xie and Hung, 1994), IL-1 receptors (Curtis et 
al.,  1990),  and  growth  hormone  receptors  (Lobie et  al., 
1994) have been shown to associate with the nucleus using 
a  variety of techniques.  In  general,  the  time  course  for 
translocation of these receptors is similar to that observed 
in this study. Maximal levels are reached within 1-2 h after 
the addition of the ligand to the cells. In the case of EGF 
receptors,  a  specific  interaction  with  chromatin  (Rako- 
wicz-Szulczynska et al., 1989)  has been proposed. 
Our results indicate that the majority of FGF receptor in 
the nucleus of FGF-2-treated cells arises from the cell sur- 
face. Furthermore, several pieces of evidence indicate that 
this receptor is full length. First, the size of the receptor as 
detected by immunoblotting is consistent with full-length 
receptor. Second, nuclear receptor can be detected using 
either an antibody to the extracellular domain or an anti- 
body  to  the  COOH-terminal  domain  of  the  receptor. 
These data imply that a specific nuclear transport mecha- 
nism  for  the  FGF  receptor  must  exist.  Specific  nuclear 
The Journal of Cell Biology, Volume 134, 1996  534 Figure 6.  Fractionation of Swiss 3T3 fibroblast nuclei.  Quiescent 
cells were untreated (lanes 1-4) or treated for 60 min with 50 ng/ 
ml FGF-2 (lanes 5--8). Membrane-depleted nuclei (lanes I and 5), 
double detergent-treated  nuclei (lanes 2 and 6), nuclear matrix 
(lanes 3  and  7),  and peripheral  nuclear matrix  (lanes 4 and 8) 
were isolated  as described  (Fey et  al.,  1986; Dworetsky et al., 
1990; Payrastre et al., 1992), and equal amounts of protein from 
each fraction were analyzed for the presence of FGF receptors by 
SDS-PAGE and immunoblotting with the mAb against the extra- 
cellular domain of FGFR-1. Similar  results were obtained in five 
independent  experiments  of identical  design.  Molecular  mass 
markers (in kilodaltons) are on the right. 
transport is generally thought to occur via nuclear localiza- 
tion sequences (NLS) (Silver,  1991; Dingwall and Laskey, 
1991).  Although  a  close  examination  of the  primary  se- 
quence of FGFR-1 does not reveal the presence of any ob- 
vious NLS, there  are  two sequences  in  the receptor  that 
have weak homology to well-characterized NLS (Dingwall 
Figure 7.  Tyrosine kinase activity of nuclear FGFR-1. (A) Quies- 
cent cells were untreated (CT) or treated for 60 rain with 50 ng/ 
ml FGF-2 (FGF). Nuclei were isolated as described (Schreiber et 
al., 1989), and nuclear proteins were solubilized  by sonication in 
Triton X-100 buffer. Immunoprecipitates were prepared using ei- 
ther an antibody specific for the COOH terminus of FGFR-1 (+) 
or normal rabbit IgG (-), and the immune complexes were phos- 
phorylated with ['y32p]ATP and analyzed by SDS-PAGE and au- 
toradiography.  (B)  Quiescent cells  were treated  with 50 ng/ml 
FGF-2 for 60 min, and nuclear proteins were solubilized  as de- 
scribed in (A). Immunoprecipitates were prepared using an anti- 
body specific for the COOH terminus of FGFR-1 in the presence 
(1) or absence (2) of the cognate peptide. The immune complexes 
were phosphorylated and  analyzed as  described  in A.  Arrow- 
heads indicate phosphorylated bands corresponding to FGFR-1. 
Similar  results were obtained in three independent experiments 
of identical design.  Molecular mass markers (in kilodaltons) are 
on the right. 
Table I. Nuclear Tyrosine Kinase Activity 
Control  +FGF-2 
Nuclei  1.0  1.14 __ 0.31 
Nuclear matrix  1.0  2.14 _+ 0.32 
Peripheral nuclear  1.0  2.22 --- 0.22 
matrix 
Protein tyrosine kinase activity in nuclei and subnuclear fractions was assayed in un- 
treated cells (control),  and cells that were treated with 50 ng/ml FGF-2 for 60 min 
(+ FGF-2) as described in Materials and Methods.  The results for FGF-2-treated cells 
are presented relative to the activity in the equivalent fraction from untreated  cells. 
The data are the average from three independent experiments -+SD. 
and Laskey, 1991). The first potential  NLS is located be- 
tween  the first and second Ig loops of FGFR-1  and con- 
sists of a  pair of basic amino acids separated from a  basic 
cluster, in which three out of the next six amino acids are 
basic, by a stretch of seven amino acids. The second poten- 
tial NLS is located in the cytoplasmic juxtamembrane  do- 
main of FGFR-1  and consists of two pairs of basic amino 
acids  separated  by a  stretch  of 18 amino  acids.  Alterna- 
tively, since proteins that have had their nuclear targeting 
sequences deleted can still be transported to the nucleus as 
part of a protein complex (Dingwall and Laskey, 1991), a 
similar process could apply to the FGF receptor. It is not 
known how the internalized receptor is shuttled through a 
vesicular pathway, eventually arriving at the nuclear mem- 
brane.  There  is  no precedent  for this  type  of trafficking 
pathway, except in the reports of other nuclear-associated 
growth factor receptors (see above). Consistent with inter- 
nalization,  the  cell  surface  to  nucleus  pathway  does  not 
function at low temperatures (Fig. 3). 
On a  final note, the observation that translocated  FGF 
receptors concentrate in the nuclear matrix is particularly 
intriguing. This matrix is thought to be instrumental in the 
regulation  and coordination of gene expression  (Fey and 
Penman,  1988;  Dworetsky  et  al.,  1990;  Stuurman  et  al., 
1990). Its composition is distinct in different tissues and in 
different cell types, and can change dramatically as a func- 
tion of differentiation (Fey and Penman, 1988; Dworetsky 
et al.,  1990; Stuurman et al.,  1990). The presence  of FGF 
receptors  in  this  particular  nuclear  fraction  suggests  that 
they could be playing a role in regulating the expression of 
a  set of FGF-2-dependent  genes.  If so, the identification 
of specific nuclear  substrates  for different  FGF receptor 
isoforms may help explain the specificity of the mitogenic 
and  differentiation  response  of cells  to  similar  signaling 
pathways. 
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